Paul Andrea's most recent trade in Zentalis Pharmaceuticals Inc was a trade of 934,041 Common Stock done . Disclosure was reported to the exchange on Feb. 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals Inc | Andrea Paul | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 934,041 | 1,084,014 | - | 0 | Common Stock | |
| Zentalis Pharmaceuticals Inc | Andrea Paul | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 124,714 | 124,714 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Andrea Paul | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.71 per share. | 03 Feb 2025 | 13,230 | 1,070,784 | - | 1.7 | 22,643 | Common Stock |
| Zentalis Pharmaceuticals Inc | Paul Andrea | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 112,500 | 153,283 | - | 0 | Common Stock | |
| Zentalis Pharmaceuticals Inc | Andrea Paul | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 112,500 | 112,500 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Paul Andrea | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Paul Andrea | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 11.54 per share. | 01 Feb 2024 | 3,310 | 149,973 | - | 11.5 | 38,197 | Common Stock |
| Zentalis Pharmaceuticals Inc | Andrea Paul | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 59,217 | 59,217 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Andrea Paul | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 40,783 | 40,783 | - | 0 | Common Stock |